Business Wire

Esmark’s Second Donation of $25,000 to Aid Ukrainian Refugees Fleeing to Slovakia Brings Contribution Total to $50,000; Company Rallies Nearly $12,000 in Additional Support

Share

Esmark Inc. today announced that Chairman & CEO James P. Bouchard and long-time friend Martina Roda have made a second donation of $25,000 USD to aid and support Ukrainians seeking refuge in Košice, Slovakia. This is the Company’s second donation to City of Košice, a city led by Mayor Ing. Jaroslav Polaček, to aid Ukrainians fleeing to Slovakia.

As of April 5, more than 302,700 Ukrainian refugees have entered Slovakia, according to a verified operational data portal.

The Company’s donations to the relief efforts now total $50,000 USD. In March, Esmark announced an initial donation of $25,000 USD and—in an effort to mobilize others to help—offered to match donations up to an additional $25,000 USD. To date, Esmark was directly notified of nearly $12,000 USD in donations made by Americans to support Ukrainian refugees.

Bouchard is a former U.S. Steel executive vice president and statutory representative of the Slovak Republic, transforming East Slovakian Ironworks, Košice–now known as U.S. Steel Košice–in Slovakia after U.S. Steel acquired it. Bouchard and Roda’s donations totaling $50,000 were made on behalf of the former U.S. Steel American and Slovak Commercial teams.

“While we are proud and grateful for the nearly $12,000 in donations made by Esmark friends, we couldn’t wait another moment to provide additional monetary support to the city Košice,” said Bouchard. “We are working directly with the Mayor’s office which ensures our funds are delivered immediately, enabling them to take swift action and help these refugees with humanitarian support.”

The funds from the initial donation were used to:

- Rent an agency as organizational and technical support in the center for Ukrainian refugees;

- Provide provisions and organization of Slovakian volunteers; and

- Coordinate temporary accommodation and provide provisions to Ukrainian refugees.

“The initial $25,000 from Jim and Martina enabled us to mobilize and organize more quickly,” said Košice City Mayor Ing. Jaroslav Polaček. “We are very grateful for the additional $25,000 of support, which we will focus mainly on providing transportation, accommodation and food especially for families with young children. “

“We cannot standby as we hear the first-hand accounts from our friends on the ground in Slovakia and continue to watch these events unfold on the news,” said Roda. ”We commend the Mayor, volunteers and all people of Košice who are providing much needed humanitarian support to their Ukrainian neighbors.”

Esmark and Bouchard have a history of and commitment to helping others in need. Over the last 15 years, more than $10 million has been donated to humanitarian relief and children’s charities.

About Esmark, Inc.

Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye